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Statins in patients with COVID-19: a
retrospective cohort study in Iranian
COVID-19 patients
Payam Peymani1,2,3†, Tania Dehesh4†, Farnaz Aligolighasemabadi5, Mohammadamin Sadeghdoust5,
Katarzyna Kotfis6, Mazaher Ahmadi7, Parvaneh Mehrbod8, Pooya Iranpour9, Sanaz Dastghaib10, Ahmad Nasimian11,
Amir Ravandi12, Biniam Kidane13, Naseer Ahmed14,15, Pawan Sharma16, Shahla Shojaei17, Kamran Bagheri Lankarani1,
Andrzej Madej18, Nima Rezaei19,20, Tayyebeh Madrakian7, Marek J. Los21, Hagar Ibrahim Labouta17,
Pooneh Mokarram3,22† and Saeid Ghavami1,3,15,18,23*†

Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection has profoundly affected the lives of millions of people. To date, there is no
approved vaccine or specific drug to prevent or treat COVID-19, while the infection is globally spreading at an
alarming rate. Because the development of effective vaccines or novel drugs could take several months (if not
years), repurposing existing drugs is considered a more efficient strategy that could save lives now. Statins
constitute a class of lipid-lowering drugs with proven safety profiles and various known beneficial pleiotropic
effects. Our previous investigations showed that statins have antiviral effects and are involved in the process of
wound healing in the lung. This triggered us to evaluate if statin use reduces mortality in COVID-19 patients.
Results: After initial recruitment of 459 patients with COVID-19 (Shiraz province, Iran) and careful consideration of
the exclusion criteria, a total of 150 patients, of which 75 received statins, were included in our retrospective study.
Cox proportional-hazards regression models were used to estimate the association between statin use and rate of
death. After propensity score matching, we found that statin use appeared to be associated with a lower risk of
morbidity [HR = 0.85, 95% CI = (0.02, 3.93), P = 0.762] and lower risk of death [(HR = 0.76; 95% CI = (0.16, 3.72), P =
0.735)]; however, these associations did not reach statistical significance. Furthermore, statin use reduced the
chance of being subjected to mechanical ventilation [OR = 0.96, 95% CI = (0.61–2.99), P = 0.942] and patients on
statins showed a more normal computed tomography (CT) scan result [OR = 0.41, 95% CI = (0.07–2.33), P = 0.312].
(Continued on next page)
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Conclusions: Although we could not demonstrate a significant association between statin use and a reduction in
mortality in patients with COVID19, we do feel that our results are promising and of clinical relevance and warrant
the need for prospective randomized controlled trials and extensive retrospective studies to further evaluate and
validate the potential beneficial effects of statin treatment on clinical symptoms and mortality rates associated with
COVID-19.
Keywords: COVID-19, SARS-CoV-2, Statins, Repurposing, Pleiotropic effects, Retrospective study

Background
The novel coronavirus, SARS-CoV-2, causing coronavirus disease 2019 (COVID-19) is a major health threat
that was declared a global pandemic by the World
Health Organization (WHO) in March 2020 [1–3]. Since
the outbreak in December 2019, a considerable number
of people has suffered from a severe acute respiratory
infection that causes respiratory failure, the need for intubation, and prolonged mechanical ventilation [4]. Currently, the management of COVID-19 remains mostly
supportive and depends on the severity of the disease,
ranging from no support in asymptomatic patients to intubation and mechanical ventilation to manage acute respiratory distress syndrome (ARDS) in severe cases [5].
During the early stages of the pandemic, it was theorized
that respiratory failure in COVID-19 may differ from
typical ARDS [6]. These differences include the presence
of good lung compliance, lack of pulmonary vasoconstriction, significant shunting and poor oxygenation, and
concomitant features of thrombotic microangiopathy
with endothelial dysfunction [7–9].
Apart from respiratory symptoms, most patients infected with SARS-CoV-2 have an increased risk of cardiovascular complications and thromboembolism,
causing cerebrovascular events, deep vein thrombosis, or
pulmonary embolism, further complicating the postinfection course. Patients suffering from COVID-19 frequently present with multi-morbidity (i.e., co-existence
of multiple co-morbidities), including hypertension, cardiovascular disease, and diabetes. A retrospective analysis of 72,314 COVID-19 cases from China showed that
patients with cardiovascular diseases exhibited significantly higher mortality (10.5% vs. 2.3%) [10]. The use of
statins has been associated with a marked reduction in
the risk of death from cardiovascular disease in the general population. Therefore, it has been proposed that statins through their pleiotropic modes of action, which
include improvement of endothelial function, and antiinflammatory and antithrombotic effects [11–13], may
therapeutically benefit COVID-19 patients. A recent
retrospective investigation on 13,981 patients with
COVID-19 (Hubei Province, China), of which 1219 patients received statins, revealed that statin use was associated with reduced mortality [14].

Statins are conventionally used as cholesterol-lowering
drugs, via inhibition of the mevalonate pathway, for
first-line therapeutic prevention of atherosclerotic cardiovascular diseases [15, 16]. The discovery of their
pleiotropic effects, independent of the cholesterol pathway, further attracted attention to this class of drugs
[17]. The decreased mortality rate from cardiovascular
diseases following statin consumption was attributed to
both the lipid-lowering effect and enhancement of vascular endothelial function [18–20]. The latter statineffect has also been observed in other patient populations, including diabetics [21, 22] and women with polycystic ovary syndrome [23]. Various mechanisms have
been reported for the statin-mediated improvement of
endothelial function and include reducing remnant lipoproteins [24], modulating the high mobility group box 1/
toll-like receptor 4(HMGB1/TLR4) pathway [25], inhibiting miR-133a expression [26], inducing nitric oxide
release [27], affecting Kruppel-like factor 2 signaling
[28], and decreasing the level of acute-phase proteins
(like C-reactive protein) [29]; of note, this last mechanism is also involved in the anti-inflammatory effects of
statins [29, 30]. Due to their anti-inflammatory properties, statins showed beneficial effects in hypertensive patients with normal cholesterol levels [19, 20]. Several
studies have identified the activation of autophagy as
one of the primary molecular mechanisms underpinning
the anti-inflammatory effects of statins [31–33].
In the current retrospective study, we investigated
whether statin use is associated with improved survival
and clinical outcome in COVID-19 patients who were
hospitalized in the Ali Asghar Hospital, Iran.

Methods
Patient recruitment

This was a retrospective study involving a population of
COVID-19 patients (ethics approval: IR.SUMS.REC.1399.151, Shiraz University of Medical Sciences)
treated in a single tertiary hospital in Shiraz, Iran (ALIA
SGHAR Hospital), between March 1st and May 30th,
2020. We specifically focused on those patients who
were discharged or had died by the end of May 2020
(Fig. 1). Hospitalized patients with the following inclusion criteria were evaluated: COVID-19 pneumonia
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Fig. 1 Flow-chart of patient enrolment and summary of the inclusion and exclusion criteria. HR: Hazard Ratio; P: P-value; P S: Propensity Score; In
PS: Invers Propensity Score

confirmed as per WHO criteria, including a positive
SARS-CoV-2 polymerase chain reaction (PCR) test of respiratory (nasopharynx, oropharynx) specimens, and evidenced by chest X-ray or chest computed tomography
(CT) scan. The CT images were reviewed by an expert
radiologist who was blind to the clinical information.
Each CT scan was scrutinized for the presence of important radiologic features, including ground-glass opacity (GGO), consolidation, pleural effusion, septal
thickening, and lymphadenopathy. The Radiological Society of North America Expert Consensus guidelines
were implemented for the diagnosis of positive cases
[34]. The peripheral bilateral GGOs, GGOs of rounded
morphology, reverse halo sign, and other indications of
organizing pneumonia were regarded as typical for
COVID-19 pneumonia. A radiologic severity score was
applied in case of abnormal chest CT findings. Patients
were also required to meet the following oxygenation inclusion criteria: SPO2 ≤ 93% or PaO2/FiO2 < 300 mmHg
< 300 mmHg. The exclusion criteria were: HIV, hepatitis
B or C, influenza virus, or active tuberculosis infection;
suspected active bacterial, fungal, or any other infections
besides COVID-19; age < 19 and > 85 years old. In
addition, patients with autoimmune or neoplastic diseases were excluded as they were using immunemodulators and/or anti-inflammatory medications or
participated in drug clinical trials.

Initially, a total of 459 patients were considered eligible for inclusion. Of these patients, 34 were excluded in the primary screening since they did not
meet the age criteria (Fig. 1). During the first phase
of our investigation, 48 patients were transferred to
other hospitals and excluded from the study because
of the inability to follow-up. An additional 227 patients were excluded because important aspects of
their medical records were missing (Fig. 1). Ultimately, a total of 150 laboratory-confirmed COVID-19
patients were included in this study, of which 75 had
a history of statin therapy and still used statin at the
time of hospitalization. Patients using statins were
matched with those that did not according to specific
confounders, such as duration of the disease, COVID19 medication, stage of the disease, history of the
underlying disease, and age. Demographic, clinical
treatment, and laboratory data (including serial samples for viral RNA detection) were extracted from the
electronic medical records. All data were checked by
the physicians and a researcher adjudicating any differences in the interpretation by the primary radiologists. After data collection, univariable logistic
regression was performed to screen for predictors,
after which multivariable logistic regression was conducted to evaluate the effects of statin therapy and
other predictors on patient recovery.
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Statistical analysis

Cox proportional-hazards regression models were used
to estimate the association between statin use and risk
of death. The proportional hazard (PH) assumption was
checked for all predictors with the Schoenfeld residuals
analysis test [35] before model building. The PH assumption is very important to Cox regression; it means
that the ratio of the hazards for any two individuals is
constant over time. For example, if gender is one of the
predictors in the Cox model and the hazard of death for
men is twice as high as for women, this must be constant over time. It dictates that time-varying predictors
cannot enter the PH Cox model [35].
First, univariate Cox regression was conducted for
each predictor. Variables that had a significant association with the hazard of death in this analysis were subsequently entered into the multivariate Cox regression.
To adjust for the effects of confounders and estimate
the pure association between statin consumption and
time until death, we implemented four strategies: multivariate Cox regression, Weighted PH Cox, PH Cox after
propensity score matching, and PH Cox adjusted with
propensity score. In our study, individual matching was
very difficult or even impossible because protecting the
patient’s life is a priority and all physicians want to prevent their patients from dying; therefore, physicians
often prescribe several antibiotics and antivirals simultaneously. Consequently, there were several confounders,
such as drugs and clinical-, laboratory-, and CTcharacteristics.
A confounder is a variable that simultaneously has an
association with the exposure and the outcome. In the
statistical analysis of observational data, there is no
randomization of the participants in treatment groups.
Therefore, the participant populations are not homogeneous based on their characteristics and clinical variables. For example, in our study, patients in the statin
and non-statin groups were not subjected to the exact
same amount or type of antivirals, antibiotics and/or
other drugs. Multiple drug-related, laboratory, and characteristic variables were different between these groups;
such heterogeneous variables led to the bias estimation
of the statin effect.
We used propensity score methods to minimize the effects of confounding factors. The propensity score analysis is a statistical technique that estimates the pure
effect of treatment and removes or reduces the effect of
other confounding variables. By using this method, the
effects of all confounding variables are summarized into
a score (the propensity score). The individual propensities were estimated with the use of a multivariable logistic regression model that included all confounding
covariates; statin use was considered the outcome in this
approach.
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We performed three adjustment procedures with respect to the propensity score. First, the individual propensity scores were inversed to calculate the inverse
propensity score weights [36]. Analysis using the
Weighted Cox regression model was subsequently conducted with these weights (Weighted PH Cox with inverse propensity score as weight). Second, since each
individual has a propensity score, subjects from the two
groups (statin vs no statin) could be matched based on
their scores [37]. In the propensity score matching analysis, the nearest-neighbor method was applied to create
the best matches (PH Cox after propensity score matching). In the third adjustment procedure, the propensity
score was entered in the multivariate Cox regression as
an additional covariate (PH Cox adjusted with propensity score). For the secondary analysis, we used logistic
regression and the outcome was changed to CT result
and mechanical ventilation. Multiple imputations were
used to handle the missing data [38]. All statistical analyses were performed using R software, version 4.02 (R
Project for Statistical Computing).

Results
For the 150 recruited participants with COVID-19 that
met the inclusion criteria, the mean duration of
hospitalization was 6.84 ± 4.35 days. The majority of patients was retired (29.7%) and/or stayed occupied doing
housework (31.8%). The mean age and BMI were
54.69 ± 4.35 years and 26.27 ± 3.68, respectively. Followup with these patients started at admission and continued for 27 days. Over this period, 19 patients died from
COVID19, whereas the other 131 patients recovered and
were discharged from the hospital. Three different types
of statin were used among the 75 patients on statins:
atorvastatin (94.7%), rosuvastatin (2.7%), and simvastatin
(2.7%). In the statin group, 14% of patients had been
using statins for over 5 years, 22% for 1–5 years, and the
remaining 64% for less than 1 year before hospital admission. The mean time of statin use during
hospitalization was 7.37 ± 4.84 (SD) days.
Patients that used statins (40 mg daily) because of
hyperlipidemia were older (65.61 vs. 58.77 years of age,
P < 0.001) and had a higher prevalence of comorbidities,
including hypertension (48% vs. 10.7%, P < 0.001), type 2
diabetes (33.3% vs. 9.3%, P < 0.001), cardiovascular disease (2.7% vs. 0%, P < 0.001), cerebrovascular diseases
(10.7% vs. 1.3%, P < 0.001), and chronic kidney diseases
(25% vs. 8%, P < 0.001), than those without statin therapy. On average, the statin group exhibited significantly
increased leukocyte polymorphonuclear (PMN) percentages (4.99 ± 2.55 vs. 4.94 ± 3.04) and reduced lymphocyte
counts (1.32 ± 0.84 vs. 1.79 ± 0.86) as compared to the
non-statin group (P = 0.01) (Table 1).
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The baseline patient characteristics are shown in Table 1,
both in the unmatched and propensity score-matched
samples. Before matching individuals from the two groups
(statin vs non-statin) based on the propensity score, some
variables showed different distribution; however, after
matching, the majority showed a similar distribution in
both groups. In the unmatched samples, statin exposure
differed according to age, addiction status, hypertension,
diabetes, cardiovascular disease, chronic kidney disease,
dyspnea, oxygen saturation (SpO2), PMN percentage,
lymphocyte count, prothrombin time, linezolid treatment,
and mechanical ventilation (at least P < 0.05 for all).
The distribution of the estimated propensity scores
among statin and non-statin patients is shown in Fig. 2.
As can be clearly observed, the histogram and density
distribution of the estimated propensity scores were
more balanced after adjustment. This shows that the
two groups became more similar when considering mutual confounders that may affect the association between
the main exposure variable (statins) and survival time.
The C-statistic of the propensity score model was 0.75.
Figure 3 shows the Kaplan–Meier curve of the statin
and non-statin groups. This plot suggested that before
any adjustment (naive data) the statin group had a lower
survival compared to the non-statin group; however, this
difference was not statistically significant. (P = 0.16). The
proportional hazard (PH) assumption was checked and
approved for all the characteristic variables before conducting PH Cox model analyses (not shown). The crude
and adjusted hazard ratios (HRs) for the association of
characteristic variables on survival time are shown in
Table 2. In the crude, unadjusted analysis, patients on
statins seemed more likely to have a death event but this
did not reach significance [HR = 2.21, 95% CI = (0.71,
6.90), P = 0.174]. The variables that showed a significant
association in the univariate model (crude) were entered
into the multivariate Cox regression model for adjustment purposes. In the multivariate Cox model, only
mechanical ventilation had a significant effect on survival. Interestingly, the adjusted HR in the multivariate
model that included mechanical ventilation was associated with an apparent lower risk of mortality in
COVID19 patients on statins compared to non-statin
users [HR = 0.92, 95% CI = (0.21,4.16), P = 0.918]; although a promising observation, this association was not
statistically significant. Figure 4 clarifies and highlights
the difference between crude and propensity scoreadjusted Cox regression plots for patient survival in the
statin and non-statin groups. The results of five distinct
Cox models with different adjustments are outlined in
Table 3. No association was found between statin use
and reduced mortality survival in the Cox analysis with
inverse propensity score weighting (weighted Cox regression) [HR = 0.94; 95% CI = (0.22, 4.17), P = 0.923].

Based on a Cox model after propensity score matching,
the HR for the statin group appeared to be associated
with a lower risk of mortality [HR = 0.85, 95% CI = (0.02,
3.93), P = 0.762]. Similarly, additional propensity score
analysis results (Cox regression with propensity score
adjustment, model 5) also revealed that statin use was
potentially associated with a decreased hazard of death
[(HR = 0.76; 95% CI (0.16, 3.72), P = 0.735)]. Although
these associations did not reach statistical significance,
they do indicate that statin use might increase survival
of COVID19 patients, and that future prospective clinical trials and extensive retrospective studies are warranted to validate the potential therapeutic potential of
statins in the amelioration of clinical symptoms and
mortality rate associated with COVID19.
As a secondary outcome, we used logistic regression
to analyze the association of statin use with the incidence of invasive mechanical ventilation and abnormal
CT results in COVID19 patients. After adjusting with
the propensity score, statin consumption was associated
with a lower chance of being subjected to mechanical
ventilation [OR = 0.96, 95% CI = (0.61–2.99), P = 0.942].
In addition, patients in the statin group appeared less
likely to present with abnormal CT results [OR = 0.41,
95% CI = (0.07–2.33), P = 0.312] (Table 4).
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Discussion
The results on statin use and its potential benefits for
COVID-19 patients are controversial. In a recent metaanalysis, it was reported that “statin use did not improve
in-hospital outcomes of COVID-19 infections” [39]; this
analysis included 9 studies with a total of 3449 patients.
The results showed that statin use did not improve the
outcome severity [OR = 1.64, 95% CI: (0.51–5.23), P =
0.41, I2 = 93%, random-effect modelling] or the mortality
rate associated with COVID-19 infection [OR 0.78, 95%
CI: (0.50–1.21), p = 0.26, I2 = 0%, fixed-effect modelling]
[39]. This finding might be due to the statistical analysis
method used. In an investigation on the use of statins in
chronic renal disease patients with COVID-19, it was
shown that statins reduced “the risk of neutrophilia
[OR-0.10, 95% CI: (0.01-0.69)]” but did not affect the
mortality in these patients [40]. Conversely, a relatively
large retrospective study on 13,981 patients with
COVID-19 (Hubei Province, China) revealed that statin
use decreased all-cause mortality from 9.4 to 5.2% (a
total of 1219 patients received statins) [14]. Furthermore,
a recent investigation showed that statin use decreased
the in-hospital mortality in COVID-19 patients with diabetes [41]. It has also been reported that for patients
using statin during hospitalization the risk of ICU admission is reduced when compared to non-statin users
[42], and that statin use decreased the risk of invasive
mechanical ventilation in COVID-19 patients [43].
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Table 1 Characteristics and comparison of patient groups (statin vs no statin), before and after propensity score matching
Parameters

Unmatched

Characteristics variables

Statin
(75 patients)

No statin
(75 patients)

P-value

Statin
(75 patients)

Matched
No statin
(75 patients)

P-value

Age [years]

65.61 ± 13.22

58.77 ± 16.01

< 0.001

63.59 ± 13.18

61.72 ± 15.83

0.433

BMI

25.92 ± 4.02

26.61 ± 3.26

0.270

25.81 ± 3.91

25.46 ± 3.16

0.545

0.247

0.740

Gender, n (%)
Male, n (%)

47 (62.7)

40 (53.3)

Female, n (%)

28 (37.3)

35 (46.7)

45 (60)

43 (57.3)

30 (40)

32 (42.7)

Addiction status, n (%)

14 (18.7)

1 (1.3)

0.001

11 (14.66)

7 (9.33)

0.315

Heart rate, beats per min

91.04 ± 18.13

Respiratory rate, breathes per min

19.56 ± 3.85

94.20 ± 14.56

0.241

91.02 ± 18.11

92.12 ± 11.82

0.660

19.44 ± 2.45

0.970

19.52 ± 2.31

19.42 ± 2.22

0.746

Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)

130.61 ± 23.23

124.28 ± 17.17

0.246

129.58 ± 22.19

127.55 ± 11.1

0.448

78.01 ± 13.23

78.52 ± 11.56

0.841

78.01 ± 12.98

78.08 ± 11.58

0.972

Triage vital signs

Body temperature (°C)

37.45 ± 1.14

37.41 ± 1.04

0.787

37.31 ± 1.09

37.22 ± 1.02

0.602

Oxygen saturation (SpO2)

87.65 ± 6.52

91.74 ± 4.60

< 0.001

88.92 ± 5.88

90.23 ± 3.82

0.108

4 (5.3)

8 (10.3)

0.367

6

7

> 0.999

Sign and symptoms
Chest pain, n (%)
Dyspnea, n (%)

62 (82.7)

49 (65.3)

0.025

58

52

0.268

Cough, n (%)

51 (68)

58 (77.3)

0.309

53

51

0.068

Headache, n (%)

13 (17.3)

19 (25.3)

0.319

15

17

0.690

Comorbidities
Hypertension, n (%)

36 (48)

8 (10.7)

< 0.001

31

12

0.001

Diabetes, n (%)

25 (33.3)

7 (9.3)

< 0.001

21

10

0.524

Cardiovascular disease, n (%)

2 (2.7)

0 (0)

< 0.001

2

1

> 0.999

Respiratory disease, n (%)

9 (12)

10 (13.3)

> 0.999

8

9

0.229

Chronic kidney disease, n (%)

19 (25)

6 (8)

0.004

15

8

0.113

Laboratory measures
PMN percent (%)

4.99 ± 2.55

4.94 ± 3.04

0.010

4.94 ± 2.31

4.93 ± 2.82

0.981

Lymphocyte count in serum

1.32 ± 0.84

1.79 ± 0.86

0.001

1.38 ± 0.71

1.61 ± 0.74

0.054

Prothrombin time (PT), (s)

35 ± 17.43

15.70 ± 3.34

< 0.001

31.01 ± 11.07

19.36 ± 2.99

< 0.001

International Normalized Ratio (INR)

1.59 ± 0.62

1.54 ± 0.55

0.602

1.58 ± 0.61

1.56 ± 0.45

0.819

C-reactive protein (CRP), (ml/dl)

78 ± 30.34

24.82 ± 21.46

0.112

Vancomycin, n (%)

33 (44)

35 (46.7)

0.743

33

34

0.870

Linezolid, n (%)

31 (41.3)

12 (16)

0.001

28

16

0.031

Ceftriaxone, n (%)

27 (36)

30 (40)

0.614

28

29

0.866

Azithromycin, n (%)

17 (22.7)

21 (28)

0.453

19

20

0.852

Ribavirin, n (%)

8 (10.7)

10 (13.3)

0.615

8

9

0.797

Lopinavir/Ritonavir, n (%)

40 (53.3)

36 (48)

0.514

39

37

0.744

Oseltamivir, n (%)

42 (56)

37 (49.3)

0.414

41

38

0.624

Hydroxychloroquine, n (%)

67 (89.3)

63 (84)

0.377

65

65

> 0.999

Glucocorticoids, n (%)

10 (13.3)

4 (5.3)

0.092

9

6

0.414

Antibiotics therapy

Antiviral therapy

Other therapy
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Table 1 Characteristics and comparison of patient groups (statin vs no statin), before and after propensity score matching
(Continued)
Parameters

Unmatched

Matched

Characteristics variables

Statin
(75 patients)

No statin
(75 patients)

P-value

Statin
(75 patients)

No statin
(75 patients)

P-value

Salbutamol, n (%)

25 (33.3)

15 (20)

0.065

21

18

0.577

Seroflo, n (%)

12 (16)

12 (16)

> 0.999

12

12

> 0.999

30 (40)

16 (21.3)

0.013

27

19

0.464

Respiratory support
Mechanical ventilation, n (%)

BMI body mass index; P-values were calculated by Mann-Whitney U test for non-normally distributed continuous variables and Fisher’s exact test or χ2 test for the
categorical variables; P-value less than 0.05 was considered significant

Based on our overall results, we feel that there is an indication that the use of statins may be linked to a lower
risk of COVID19 mortality, even though this association
did not reach statistical significance [HR = 0.924, 95%
CI = (0.205, 4.157), P = 0.918]. In addition, statins significantly reduced the need for mechanical ventilation and
improved lung CT in COVID-19 patients. Although
promising and clinically relevant, our observed associations between statin use and survival of COVID19

patients were not statistically significant (likely due to
impaired power of our analysis as a result of the many
patients that had to be excluded) and need to be validated in prospective clinical trials and extensive retrospective studies. Considering the various documented
pleotropic effects of statins and the results presented
here, we anticipate positive effects of statin use on the
clinical outcomes of COVID-19 patients. In a recent investigation comprising 3654 individuals in Germany, it

Fig. 2 Histogram and density distribution plots of the estimated propensity scores, before and after propensity score adjustment in statin and
non-statin patient groups. The left side of the figure (unadjusted) shows that the non-statin group had more density on the right side of the plot
versus the statin group that had more density on the left side of the plot. After adjustment (right side of the figure), both groups displayed
similar densities. The results show that the two groups became more similar when considering mutual confounders that may affect the
association between the main exposure variable (statins) and survival time. The C-statistic of the propensity score model was 0.75
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Fig. 3 Kaplan-Meier plot comparing the survival time (in days) between the statin and non-statin groups. This plot suggests that before any
adjustment (naive data) mortality was lower in the statin than the non-statin group. However, the P-value of the log-rank test (P = 0.16) did not
indicate any significant difference

was demonstrated that using statins was associated with
asymptomatic COVID-19; accordingly, it was postulated
that statins might promote SARS-CoV-2 transmission by
increasing the number of asymptomatic COVID-19 patients [44]. In contrast, a recent observational multicenter study in Italy indicated that statin use was associated with an increased risk of more severe COVID-19
[45], whereas another recent report suggested that statins did not affect mortality at all in COVID-19 patients
(4842 subjects) [46].
Pleiotropic effects of statins have been reported in several malignancies, especially respiratory infections [47,
48], acute lung injury [49], pulmonary hypertension [50],
community-acquired pneumonia, chronic obstructive
pulmonary disease [51], and interstitial lung disease [52].
Statins have shown various beneficial anti-inflammatory
and immunomodulatory properties by affecting intracellular signaling pathways [53, 54] that are independent of
their lipid-lowering ability [55]. Furthermore, antiviral
effects against the influenza virus have been demonstrated in several in vitro and in vivo studies [56–59].
Statins modulate the antiviral response in human bronchial and epithelial cells, which constitute the first line
of defense against invading pathogens [60], and significantly reduce the production of pro-inflammatory cytokines, such as TNFand IL-6, in Crandell feline

kidney cells infected with H1N1 [61]. In primary normal
human bronchial epithelial cells (NHBE) and the human
type II pneumocyte cell line A549, simvastatin attenuated viral dsRNA-induced AKT phosphorylation, STAT3
activation, and subsequent production of RANTES [62].
In another study, simvastatin was shown to reduce the
replication of H1N1 by blocking RhoA membrane
localization, actin filament condensation, Rab protein expression during endocytosis, and LC3-II protein
localization [57].
The effects of statins on the Coronaviridae family are
still under-studied. Earlier in 2015, it was proposed that
a high dose of atorvastatin may work against MERS-CoV
infections by decreasing inflammatory cytokines, and
that although statins may not be very effective in latestage patients, timely use could be vital for the survival
of MERS-CoV infected subjects [63]. Since some investigations had confirmed the association of statin therapy
with a reduction in cardiovascular outcomes and mortality in patients infected with influenza, it was also suggested that COVID19 patients, with severe damage to
lung tissue caused by a cytokine storm of inflammatory
mediators, continue statin therapy for its potential clinical benefit [64].
Several studies have provided some more mechanistic perspectives on the action of statins in relation to
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Table 2 Data analysis using the crude and adjusted Cox regression models
Parameters

Crude

Variables

HR

95% C.I for HR

P-value

HR

Adjusted
95% C.I for HR

P-value

Age

1.02

0.97–1.05

0.294

–

–

–

BMI

1.05

0.92–1.19

0.503

–

–

–

Gender (men vs. women)

1.16

0.45–3.01

0.760

–

–

–

Smoking vs. none

0.83

0.26–2.67

0.752

–

–

–

Addiction vs. none

1.63

0.45–5.93

0.462

–

–

–

0.98

0.95–1.02

0.066

–

–

–

Triage vital signs
Heart rate, beats per min
Respiratory rate, breathes per min

1.05

0.97–1.14

0.263

–

–

–

Systolic blood pressure (mm Hg)

0.96

0.94–0.99

0.005

1.01

0.98–1.05

0.507

Diastolic blood pressure (mm Hg)

0.91

0.88–0.95

< 0.001

0.95

0.88–1.04

0.244

Body temperature, Celsius degrees

1.06

0.70–1.61

0.781

–

–

–

Oxygen saturation (SpO2)

0.89

0.84–0.95

< 0.001

0.97

0.86–1.10

0.637

Sign and symptoms
Chest pain vs. none

0.51

0.06–4.25

0.531

–

–

–

Dyspnea vs. none

2.49

0.57–10.98

0.226

–

–

–

Cough vs. none

0.49

0.19–1.27

0.142

–

–

–

Headache vs. none

1.60

0.56–4.58

0.379

–

–

–

Hypertension

2.27

0.89–5.75

0.086

–

–

–

Comorbidities

Diabetes

1.55

0.59–4.01

0.369

–

–

–

Cardiovascular disease

2.38

0.93–6.06

0.070

–

–

–

Respiratory disease

1.19

0.34–4.15

0.787

–

–

–

Chronic kidney disease

4.20

1.66–10.67

0.003

2.21

0.49–9.89

0.302

PMN percent

1.04

1.05–1.16

< 0.001

1.04

0.97–1.13

0.262

Lymphocyte count

0.88

0.81–0.95

0.001

1.04

0.93–1.13

0.486

Prothrombin time (PT)

0.99

0.99–1.01

0.755

–

–

–

International Normalized Ratio (INR)

1.87

1.21–2.88

0.005

1.43

0.58–3.55

0.441

C-reactive protein (CRP), (ml/dl)

0.99

0.97–1.02

0.995

–

–

–

Serum Creatinine

1.11

1.01–1.22

0.035

1.08

0.88–1.33

0.461

Hematocrit

0.85

0.78–0.93

0.001

0.91

0.79–1.04

0.774

1.30

0.49–3.43

0.591

–

–

–

Laboratory measures

Antibiotics therapy
Vancomycin vs. none
Linezolid vs. none

0.81

0.31–2.17

0.679

–

–

–

Ceftriaxone vs. none

0.81

0.32–2.07

0.662

–

–

–

Azithromycin vs. none

0.22

0.03–1.63

0.137

–

–

–

Antiviral therapy
Ribavirin vs. none

1.04

0.30–3.62

0.948

–

–

–

Lopinavir/Ritonavir vs. none

1.33

0.51–3.48

0.562

–

–

–

3.17

1.16–8.66

0.025

0.67

0.12–3.82

0.649

0.92

0.21–4.16

0.918

Other therapy
Glucocorticoids vs. none
ARB vs. none

2.49

0.89–7.01

0.082

Statin vs. none

2.21

0.71–6.90

0.174
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Table 2 Data analysis using the crude and adjusted Cox regression models (Continued)
Parameters

Crude

Variables

HR

95% C.I for HR

P-value

HR

Adjusted
95% C.I for HR

P-value

Salbutamol vs. none

0.53

0.18–1.52

0.236

–

–

–

Seroflo vs. none

0.35

0.08–1.56

0.167

–

–

–

11.01

2.48–18.85

0.002

6.27

1.03–11.27

0.047

Respiratory support
Mechanical ventilation vs. none

HR hazard ratio, C.I confidence interval, BMI body mass index, ARB angiotensin receptor blocker
P-value less than 0.05 was considered significant

SARS-CoV-2 infection. An in silico docking study
highlighted that statins might be efficient inhibitors of
the SARS-CoV-2 main protease [65]. Moreover, selective statins (fluvastatin was more efficient than
other statins) reduced SARS-CoV-2 cell entry and
inhibited infection of human respiratory epithelial
cells in vitro by either the low pathogenic (coronavirus 229E) or highly pathogenic (2019-nCoV) coronavirus [66]. This study also reported that statin therapy
did not cause any additional risk to patients and that
some statins may have a mild beneficial effect on
COVID-19 outcome [66].
Autophagy is an important cellular mechanism against
different types of stress, including viral infection [3, 67,
68]. SARS-CoV-2 infection likely changes autophagy flux
in the infected cells and hijacks it for its replication [3].

The clinical effects of statins described to date have in
part been attributed to their impact on cellular autophagy. Indeed, several studies have reported the involvement of the autophagy pathway as a mechanism for the
protective effects of statins in the human lung [69, 70].
Using airway mesenchymal cells, we demonstrated the
potential for statins to have beneficial effects in obstructive airways diseases by induction of autophagy via upregulation of p53 [71] as well as through their effects on
other pathways, such as the unfolded protein response
[72]. Using a mouse model of asthma, simvastatin was
shown to ameliorate key asthmatic symptoms (airway remodeling and inflammation) in the lungs via autophagy
augmentation [33]. Therefore, it is conceivable that statins may target SARS-CoV-2 infection in lung epithelial
cells through autophagy(−associated) signaling.

Fig. 4 Crude survival and propensity score-adjusted Cox plots comparing the survival time (in days) between the statin and non-statin groups.
The plots highlight the difference between crude and propensity score-adjusted survival Cox regression plots for the statin and non-statin patient
populations. These plots suggest that before adjustment (left plot), the statin group displayed a lower survival time, whereas after adjustment
(right plot), statin users showed a higher survival probability; however, neither of these differences was significant

(2021) 6:3
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Table 3 The effect of statin use on COVID-19 patient survival as assessed by the crude, multivariable and propensity score analysis
P-value

Cox models

Model

HR

95% C.I for HR

Crude

1

2.21

0.71–6.90

0.174

Multivariate Cox

2

0.92

0.21–4.16

0.918

Weighted PH Cox (IPS as weight)

3

0.94

0.22–4.17

0.923

PH Cox after PS Matching

4

0.85

0.02–3.93

0.762

PH Cox adjusted with PS

5

0.76

0.16–3.72

0.735

HR hazard ratio, CI confidence interval, PH proportional hazard, PS propensity score, IPS inverse propensity score

Statins have shown modulatory effects on
angiotensin-converting enzyme 2 (ACE2) expression.
Qi and co-workers were the first to study the expression of ACE2 in cardiomyocytes of rats with cardiac
hypertrophy and reported a decreased expression of
both ACE2 mRNA and protein levels in response to
4 weeks of treatment with 5 mg/kg/day atorvastatin
[73]. Later, similar effects on aortic arteries in vascular balloon injured rats treated with the same doses
of rosuvastatin for 2 to 4 weeks were demonstrated
[74]. However, other studies presented conflicting observations. In a cellular model of vascular smooth
muscle cell hypertrophy, atorvastatin recovered the
molecular changes induced by TNF-α and increased
ACE2 mRNA expression [75]. Using a rabbit model
of atherosclerosis, an association between atherosclerosis and a reduced level of ACE2 in both renal and
cardiac tissue was established; ACE2 levels were
replenished following 3 weeks of atorvastatin administration [76]. Since the emergence of the significance
of ACE2 expression in diabetes [77], scientists have
focused on the potential role of statins in diabetes.
Aguilar and colleagues showed that atorvastatin increased ACE2 mRNA in cardiomyocytes of diabetic
cardiomyopathic rats, which was associated with a reduction in fibrosis and hypertrophy of the left ventricles [78]. These effects were attributed to the
recovered ratio of ACE/ACE2 rather than an increased level of ACE2 [78]. Further studies in diabetic
rats confirmed that statin administration increased
ACE2 mRNA in cardiac tissue from insulin-controlled
groups, although this was not accompanied by significant effects on cardiac fibrosis and reactive oxygen
species generation [79, 80]. In our current report,
33% of COVID19 cases that used statins were diabetic. Although diabetes is among the comorbidity

factors for COVID-19 mortality, none of the enrolled
diabetic COVID19 patients on statins died because of
COVID-19 infection.
Our recent investigations demonstrated that in
addition to their anti-inflammatory actions, statins inhibit tissue damage by reducing extracellular matrix synthesis in airway mesenchymal cells [81, 82]. Several
studies have shown beneficial effects of statins in the
treatment and recovery of patients with idiopathic pulmonary fibrosis and implied that statins improve lung
function by acting on fibrosis mediators [83, 84]. In
addition, statins reduce mortality in these patients and
those with interstitial lung disease [85].

Conclusion
Overall, we propose that statin use can potentially protect SARS-CoV-2-induced tissue damage and improve
lung function in COVID-19 patients via different pleiotropic effects. These effects include targeting the SARSCoV-2-induced inflammation and cytokine storm, inhibition of cellular trafficking via targeting the autophagy
pathway, mediating ACE2 expression, and decreasing
extracellular matrix biosynthesis and scar formation in
COVID-19 patients. Our current work may have some
different results than those reported in the study in
China by Zhang et al. [14], likely because of differences
in the number (limitation of our current study) and genetic background of the patients involved. Although we
could not demonstrate a significant association between
statin use and a reduction in COVID19 mortality, our
results are promising and clinically relevant and warrant
the need for prospective randomized controlled trials
and extensive retrospective studies in large and diverse
patient populations to further evaluate the potential
beneficial therapeutic effects of statin treatment on clinical symptoms and mortality rates associated with

Table 4 The results of the crude and propensity score adjusted logistic regression for the secondary outcome
Logistic regression models

Crude

Secondary outcome

OR

95% CI for OR

P-value

OR

95% C.I for OR

P-value

CT result (abnormal vs. normal)

1.77

0.61–5.14

0.295

0.41

0.07–2.33

0.312

Mechanical ventilation vs. none

2.46

1.19–5.05

0.014

0.96

0.61–2.49

0.942

OR odds ratio, CI confidence interval, PS propensity score

Adjusted with PS
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COVID-19. We believe that the use of statins could represent a strong adjuvant/adjunct therapeutic strategy in
addition to other (antiviral) therapies currently used
against COVID-19. The results of our retrospective
study provide evidence that using statins (40 mg daily)
might render a better clinical outcome for COVID-19
patients. We speculate that long-term usage of statins
prior to infection might be most therapeutically
effective.
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